(19) 世界知的所有権機関 国際事務局



(43) 国際公開日 2004年10月21日(21.10.2004)

PCT

(10) 国際公開番号 WO 2004/090541 A1

(51) 国際特許分類7: G01N 33/53, 33/50, 33/15, A61K 45/00, 31/353, A61P 9/00, 9/10, 25/00, 25/28, 35/00, 37/08

(21) 国際出願番号:

PCT/JP2004/004772

(22) 国際出願日:

2004年4月1日(01.04.2004)

(25) 国際出願の言語:

日本語

(26) 国際公開の言語:

日本語

(30) 優先権データ:

特願2003-097652 2003 年4 月1 日 (01.04.2003) TP

- (71) 出願人 (米国を除く全ての指定国について): 三菱 ウェルファーマ株式会社 (MITSUBISHI PHARMA CORPORATION) [JP/JP]; 〒5410046 大阪府大阪市中 央区平野町二丁目6番9号Osaka (JP).
- (71) 出願人 および
- (72) 発明者: 立花 宏文 (TACHIBANA, Hirofumi) [JP/JP]: 〒8130016福岡県福岡市東区香椎浜四丁目7番8号 Fukuoka (JP).
- (74) 代理人: 髙柳 昌生 (TAKAYANAGI, Masau): 〒1038405 東京都中央区日本橋本町二丁目2番6号三菱ウェル ファーマ株式会社 知的財産部 Tokyo (JP).

- (81) 指定国(表示のない限り、全ての種類の国内保護が 可能): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS. LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG. SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) 指定国(表示のない限り、全ての種類の広域保護が 可能): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), ユーラシア (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), ヨーロッパ(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

添付公開書類:

国際調査報告書

2文字コード及び他の略語については、 定期発行される 各PCTガゼットの巻頭に掲載されている「コードと略語 のガイダンスノート」を参照。

(54) Title: METHOD OF SCREENING DRUG WITH THE USE OF 67 kDa LAMININ RECEPTOR AND DRUG OBTAINED THEREBY

(54) 発明の名称: 67kDaラミニン・レセプターを用いた薬物のスクリーニング方法及びそれにより得られる薬物

(57) Abstract: It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby. A method of screening a drug having an effect of inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a nerve protecting effect, an antiallergic effect, an antiareteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease which involves the step of qualitatively or quantitatively measuring the degree of the binding of a test compound to a 67 kDa laminin receptor, and judging that the test compound is a drug having an effect of inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a nerve protecting effect, an antiallergic effect, an antiareteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease in the case where it is found out by the results of the measurement that the test compound binds to the 67 kDa laminin receptor, and a drug obtained thereby.

(57) 要約: 67kDaラミニン・レセプターを用いた薬物の新規なスクリーニング方法及びそれにより得られる薬物 被験化合物と67kDaラミニン・レセプターとの結合の度合いを定性的または定量的に測定し、 その測定結果より被験化合物が67kDaラミニン・レセプターに結合する場合にはその被験化合物が細胞増殖抑 制作用、血管新生阻害作用、癌細胞の転位活性阻害作用、神経保護作用、抗アレルギー作用、抗動脈硬化作用、及 べいできたは、クロイツフェルトヤコブ病感染阻害作用を有する薬物であると判断する工程を含む、細胞増殖抑制作 用、血管新生阻害作用、癌細胞の転位活性阻害作用、神経保護作用、抗アレルギー作用、抗動脈硬化作用、及び/ または、クロイツフェルトヤコブ病感染阻害作用を有する薬物のスクリーニング方法、並びに、それにより得られ る薬物。

名義変更届

特許庁長官 殿

1. 国際出願の表示 PCT/JP2004/004772

2. 出願人

名 称 株式会社産学連携機構九州

KYUSHU TLO COMPANY, LIMITED

あて名 〒812-8581 日本国福岡県福岡市東区箱崎6丁目10番1号

10-1, Hakozaki 6-chome, Higashi-ku, Fukuoka-shi, Fukuoka 812-8581

Japan

国籍 日本国 JAPAN

住 所 日本国 JAPAN

3. 届け出の内容 新名義人

事件との関係 米国及び日本を除く全ての指定国における出願人

名 称 株式会社産学連携機構九州

KYUSHU TLO COMPANY, LIMITED

あて名 〒812-8581 日本国福岡県福岡市東区箱崎6丁目10番1号

10-1, Hakozaki 6-chome, Higashi-ku, Fukuoka-shi, Fukuoka 812-8581

Japan

国籍 日本国 JAPAN

住 所 日本国 JAPAN

事件との関係 指定国日本における出願人

名 称 三菱ウェルファーマ株式会社

MITSUBISHI PHARMA CORPORATION

あて名 〒541-0046 日本国大阪府大阪市中央区平野町二丁目6番9号

6-9, Hiranomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-0046

Japan

国籍 日本国 JAPAN

住所 日本国 JAPAN

事件との関係 指定国米国及び日本における出願人及び全ての指定国における発明者

氏 名 立花 宏文

TACHIBANA Hirofumi

あて名 〒813-0016 日本国福岡県福岡市東区香椎浜四丁目7番8号

7-8, Kashiihama 4-chome, Higashi-ku, Fukuoka-shi, Fukuoka 813-0016

Japan

国籍 日本国 JAPAN

住 所 日本国 JAPAN

4. 添付書類の目録 (1) 譲渡証書 2通

International application No.

	THE WITTOWN DEPARTMENT OF THE	<i>)</i>	International appli			
A CT ACCIET	TO LOTTON AT OUT TO THE AT LANGUAGE		PCT/JP2	2004/004772		
A. CLASSIFI Int.Cl	ICATION OF SUBJECT MATTER L ⁷ G01N33/53, G01N33/50, G01N33	3/15 NC11/15/(252		
	A61P9/00, A61P9/10, A61P25/0	00. A61P25/28	- A61P35/00	353, - A61 P37 /N8		
_				, 1.011.07, 00		
According to In	nternational Patent Classification (IPC) or to both nation	nal classification and IPC	C			
B. FIELDS SEARCHED						
Minimum docur	mentation searched (classification system followed by c	classification symbols)				
<pre>Int.Cl⁷ G01N33/53, G01N33/50, G01N33/15, A61K45/00, A61K31/353,</pre>						
	WOIES/OU, MOIES/IO, MOIESS/C	JU, A01775/70,	. A61235/00/	, A61P37/08		
			·			
Documentation:	searched other than minimum documentation to the ext Shinan Koho 1922–1996 To	tent that such documents	are included in the			
	_	Toroku Jitsuyo Sh Jitsuyo Shinan To	ninan Koho	1994-2004 1996-2004		
Electronic data to BIOSIS	base consulted during the international search (name of (DIALOG), WPI (DIALOG), JICST (JO	idata base and, where pro	acticable, search ter	rms used)		
	(DIADOG), WEI(DIADO), OLODI(O.	OID); CH(DIM)				
- 2007 m			· · · · · · · · · · · · · · · · · · ·			
C. DOCUMEN	NTS CONSIDERED TO BE RELEVANT		, ,			
Category*	Citation of document, with indication, where a	ppropriate, of the relevan	nt passages	Relevant to claim No.		
X/A	WO 99/54356 A (THE QUEEN'S U	UNIVERSITY OF	BELFAST),	1,2/		
	28 October, 1999 (28.10.99), Full text			4-6,12-17,		
}	Full text & EP 1073679 A			25-30		
Х.	JP 2000-226329 A (Meiji Milk	k Products Co.	. Ltd.),	25-30		
Ì	15 August, 2000 (15.08.00),			- .		
	Claims (Family: none)					
	-		1			
Х	JP 2002-220340 A (Ito En, Lt	id.),]	25-30		
	09 August, 2002 (09.08.02),		1	<u> </u>		
	Claims; Par. Nos. [0005], [0020], [0021] (Family: none)					
	(ramily, none,		1			
	i					
	·					
	ı					
× Further doc	cuments are listed in the continuation of Box C.	Can actent fami				
	gories of cited documents:	See patent famil				
"A" document de	efining the general state of the art which is not considered	date and not in conf	oflict with the applicati	national filing date or priority ion but cited to understand		
to be of partic	icular relevance cation or patent but published on or after the international	the principle or theo	ory underlying the inv	vention		
filing date		considered novel of	or cannot be consider	aimed invention cannot be ered to involve an inventive		
"L" document whe	hich may throw doubts on priority claim(s) or which is blish the publication date of another citation or other	step when the docum	ment is taken alone			
special reasor	n (as specified)	considered to invo	olve an inventive ste	nimed invention cannot be tep when the document is		
'O" document refe' 'P" document put	ferring to an oral disclosure, use, exhibition or other means ablished prior to the international filing date but later than	combined with one	or more other such do	ocuments such combination		
P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family						
Date of the actual completion of the international search 18 May, 2004 (18.05.04) Date of mailing of the international search report 01 June, 2004 (01.06.04)				report		
10	18 May, 2004 (18.05.04) 01 June, 2004 (01.06.04)					
Toma and mailing	g address of the ISA/	<u> </u>				
	g address of the ISA/ se Patent Office	Authorized officer		-		
_		1				

Telephone No.

Facsimile No.
Form PCT/ISA/210 (second sheet) (January 2004)

International application No.
PCT/JP2004/004772

C-4 +		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim 1
X	JP 2001-114687 A (Mitsui Norin Co., Ltd.), 24 April, 2001 (24.04.01), Par. No. [0003] (Family: none)	25-30
P, X	TACHIBANA "A receptor for green tea polyphenol EGCG.", Nat.Struct.Mol.Biol., Vol.11, No.4, (2004) pages 380 to 381	1-30
Α .	JP 8-205885 A (La Jolla Cancer Research Foundation), 13 August, 1996 (13.08.96), & JP 3-504383 A & WO 89/11273 A & EP 452314 A & US 5180809 A	1-30
A	JP 6-219965 A (The United States of America), 09 August, 1994 (09.08.94), & JP 60-500974 A & WO 84/03946 A & US 4565789 A	1-30
	·	
	·	
,	·	
	·	
j		
İ		
·		
	·	

International application No. PCT/JP2004/004772

Box No. II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
1. Claims	al search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: Nos.: e they relate to subject matter not required to be searched by this Authority, namely:
because extent t	Nos.: 3, 7-11, 18-24 they relate to parts of the international application that do not comply with the prescribed requirements to such an hat no meaningful international search can be carried out, specifically: extra sheet.)
3. Claims because	Nos.: they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No. III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
ciaims.	quired additional search fees were timely paid by the applicant, this international search report covers all searchable rchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of
any additi 3. As only s	ional fee. ome of the required additional search fees were timely paid by the applicant, this international search report covers se claims for which fees were paid, specifically claims Nos.:
No requirestricted	ed additional search fees were timely paid by the applicant. Consequently, this international search report is to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protes	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

International application No.

PCT/JP2004/004772

Continuation of Box No.II-2 of continuation of first sheet(2)

Claims 3, 7 to 11 and 18 to 24 relate to so-called screening method-specified compounds or compounds specified exclusively by a function and, therefore, it is completely unknown what specific compounds are involved therein and what are not. Thus, these claims are described in an extremely unclear manner.

Form PCT/ISA/210 (extra sheet) (January 2004)